An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer

Rose, Peter G.; Monk, Bradley J.; Provencher, Diane; Hartney, Jean T.; Legenne, Philippe; Lane, Stephen R.

doi:10.1016/j.ygyno.2010.10.011

Cited by 6 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the 10-year relative survival rate was only 10-20%, implying that most patients experience relapse, develop chemoresistance, and eventually die. Therefore, most patients are eligible for second-line chemotherapy (23).…”

Section: Discussionmentioning

confidence: 99%

Assessment of the Applicability of Integrative Tumor Response Assays in Advanced Epithelial Ovarian Cancer

et al. 2018

View full text Add to dashboard Cite

Aim: To prospectively correlate clinical responses to second-line chemotherapy for recurrent epithelial ovarian cancer (EOC) with in vitro integrative tumor-response assay (ITRA) results. Patients and Methods: Forty-four patients with advanced EOC were enrolled from 2015-2017 at the Asan Medical Center, Seoul, Korea. ITRA comprised of two sequential histoculture drug response assays (HDRAs) of the tumor tissues. The first stage was HDRA with paclitaxelcarboplatin, paclitaxel, and carboplatin chemotherapy. The second stage was performed with surviving tumor cells from the first stage using topotecan, belotecan, gemcitabine, doxorubicin, ifosfamide, vinorelbine, and etoposide. Results: The median follow-up period was 23.35 (range=4-35.35) months. Eighteen patients (40.9%) completed the second-line chemotherapy, based on the ITRA results. The objective response rate was 38.9%. The clinical response rate was 50%; two patients (11.1%) had stable disease. The sensitivity of ITRA for predicting response was 85.7% (specificity=18.2%; accuracy=44.44%). Conclusion: ITRAs had acceptable applicability and may help choose second-line chemotherapy for patients with advanced EOC.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of the Applicability of Integrative Tumor Response Assays in Advanced Epithelial Ovarian Cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In the same way, different scheduling of a variety of non-platinum agents (e.g., gemcitabine, paclitaxel, topotecan, etc.) might be equally if not perhaps more successful and extend the PFI [46,47].…”

Section: Schedulingmentioning

confidence: 97%

Recurrent Ovarian Cancer: When and How to Treat

Hall

Rustin

2011

Curr Oncol Rep

View full text Add to dashboard Cite

Notwithstanding continuing efforts to improve the primary treatment for ovarian cancer, most patients will ultimately develop recurrent disease. The benefits of detection and early systemic treatment of recurrence are now in doubt following the presentation of the MRC/EORTC CA125 surveillance trial. The impact of secondary cytoreductive surgery on survival requires more investigation. The role of antiangiogenic and other biological agents such as PARP inhibitors is becoming increasingly important for patients as an addition or alternative to the more conventional cytotoxic therapies available. Uncertainties and choices abound both in the treatment of recurrent ovarian cancer and the timing of such interventions. This article not only explores how to treat these patients but also the controversial issue of when to treat. Educating and involving the patient in decisions about their treatment options is of paramount importance.

show abstract

“…Also, weekly dosing may allow clinicians to monitor patients more frequently. Moreover, the improved hematologic toxicity profile of the weekly dosing may allow greater tolerability in combining topotecan with other antitumor agents such as gemcitabine [20], docetaxel [21], paclitaxel [22], or carboplatin [23]. Recently, weekly topotecan had been investigated to combine with the targeted agents such as bevacizumab [24], sorafenib [25], or lapatinib [26].…”

Section: Characteristicmentioning

confidence: 99%

The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: The Kaohsiung Chang Gung experience

et al. 2015

Taiwanese Journal of Obstetrics and Gynecology

View full text Add to dashboard Cite

show abstract

An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer

Cited by 6 publications

References 22 publications

Assessment of the Applicability of Integrative Tumor Response Assays in Advanced Epithelial Ovarian Cancer

Assessment of the Applicability of Integrative Tumor Response Assays in Advanced Epithelial Ovarian Cancer

Recurrent Ovarian Cancer: When and How to Treat

The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: The Kaohsiung Chang Gung experience

Contact Info

Product

Resources

About